申请人:Becker Oren
公开号:US20120115850A1
公开(公告)日:2012-05-10
The invention relates to 5-HT
6
receptor antagonists. Novel arylamine compounds and use of these compounds and their pharmaceutical compositions, e.g., in the treatment, modulation and/or prevention of physiological conditions associated with serotonin action, such as in treating obesity, and obesity-related disorders, e.g., cardiovascular disease, digestive disease, respiratory disease, cancer and type II diabetes; and psychological disorders such as schizophrenia, are disclosed.
本发明涉及5-HT6受体拮抗剂。本发明公开了新型芳基胺化合物及其在治疗、调节和/或预防与血清素作用相关的生理状况中的应用,例如治疗肥胖症以及与肥胖症相关的疾病,如心血管疾病、消化系统疾病、呼吸系统疾病、癌症和2型糖尿病;以及精神障碍,如精神分裂症的制备及其制药组合物。